Clinical trial suggests new drug candidate for spinocerebellar ataxia may offer certain therapeutic benefits
A team has conducted a trial on the efficacy and safety of L-arginine in treating spinocerebellar ataxia type 6 (SCA6).
News Medical on MSN14h
L-arginine shows potential in treating spinocerebellar ataxia type 6
A team led by Specially Appointed Associate Professor Tomohiko Ishihara and Professor Osamu Onodera at Niigata University, along with Professor Yoshitaka Nagai at Kindai University, conducted a ...